Table 2.

Amylin derivatives as potential inhibitors of cytotoxicty affected by full-length human amylin.

Amylin derivative	Position of N-methylated residue	Decrease in cytotoxicity	Cell line used	Reference
Amylin20–25		25%	RIN-1056A	[37]
Amylin24–29		0%	RIN-1056A	[37]
Amylin12–17		0%	RIN-1056A	[110]
Amylin15–20		0%	RIN-1056A	[110]
Amylin22–27	20 and 25	20%	RIN 5fm	[65]
Amylin1–37	24 and 26	50%	RIN 5fm	[103]
Amylin13–18		50%	RIN-1056A	[111]
Amylin20–25		50%	RIN-1056A	[111]
Amylin3–6		45%	RIN 5fm	[142]
Amylin3–6	3–5	0%	RIN 5fm	[142]
Amylin9–13		40%	RIN 5fm	[142]
Amylin9–13	9, 12, and 13	0%	RIN 5fm	[142]
Amylin15–20		20%	RIN 5fm	[142]
Amylin15–20	15–17 and 19	0%	RIN 5fm	[142]
Amylin22–27		40%	RIN 5fm	[142]
Amylin22–27	23–27	0%	RIN 5fm	[142]
Amylin29–34		50%	RIN 5fm	[142]
Amylin29–34	30 and 32–34	50%	RIN 5fm	[142]